Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Working Capital Changes (2024 - 2025)

Prelude Therapeutics' Other Working Capital Changes history spans 2 years, with the latest figure at $34.4 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 25611.11% year-over-year to $34.4 million; the TTM value through Dec 2025 reached $35.5 million, up 3480.78%, while the annual FY2025 figure was $35.5 million, 3480.78% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $34.4 million at Prelude Therapeutics, up from $1.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $34.4 million in Q4 2025 and bottomed at -$1.1 million in Q2 2025.